Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.
← catalyst calendarNCT06321601 · readout in 333 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
19actual
Sites
34
Countries
Belgium, Canada, Czechia +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-10-22 | actual | When the study began enrolling |
| Primary completion | 2027-07-18 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-07-18 | estimated | The whole study's end, after follow-up |
| First posted | 2024-03-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Vasculitis
Intervention
- Drug: Avacopan — also filed as AMG 569
Primary outcomes
what the primary-completion date above is the date OFProportion of Participants Achieving Disease Remission at Week 26 According to the Pediatric Vasculitis Activities Score (PVAS)
measured Week 26
Proportion of Participants With Sustained Disease Remission at Week 52 According to the PVAS
measured Week 52
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed